Drugs in Dev. Infections and Infectious Diseases
Undisclosed
Netherlands 
Lead Product(s) : Inactivated EV D68 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : National Institutes of Health
Deal Size : $9.4 million
Deal Type : Agreement
Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine
Details : The contract will support development of a prophylactic vaccine against enterovirus D68 (EV D68). Intravacc will develop an inactivated EV D68 vaccine, based on Intravacc's proprietary Vero cell technology, from early product selection through to Phase I...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
August 09, 2020
Lead Product(s) : Inactivated EV D68 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : National Institutes of Health
Deal Size : $9.4 million
Deal Type : Agreement
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Intravacc To Develop Emergency and Conventional Covid-19 Vaccines
Details : Intravacc is focusing on emergency and conventional vaccines. Intravacc’s emergency vaccine is designed to activate T-cell responses. This emergency vaccine would aid in reduction of mortality and morbidity, thus aims to reduce the pressure on the publ...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Conestat Alpha
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharming Reports Encouraging Results from Use of RUCONEST® in COVID-19 Patients
Details : Following treatment with RUCONEST®, fever resolved in four of the five patients within 48 hours, and laboratory markers of inflammation decreased significantly (CRP, IL-6).
Product Name : Ruconest
Product Type : Protein
Upfront Cash : Inapplicable
April 21, 2020
Lead Product(s) : Conestat Alpha
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Wageningen Bioveterinary Research
Deal Size : Undisclosed
Deal Type : Partnership
Details : The aim of this partnership is to develop an intranasal vaccine to protect humans against COVID-19. The vaccine will consist of a Newcastle disease virus vector that expresses the immunogenic spike protein of SARS-CoV-2.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
April 06, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Wageningen Bioveterinary Research
Deal Size : Undisclosed
Deal Type : Partnership
Reset All
